Advertisement

Naturally Occurring Autoantibodies Against β-Amyloid

  • Jan-Philipp Bach
  • Richard DodelEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 750)

Abstract

Naturally occurring antibodies (NAbs) have been described for more than 30 years. Recently, NAbs against β-Amyloid and against other proteins involved in neurodegenerative disorders have been detected in humans. Based on the current evidence, it is hypothesized that anti-Aβ NAbs can inhibit the fibrillation and toxicity of β-aymloid, can improve cognition in a transgenic mouse model and interfere with oligomers of Aβ. Different functions of these NAbs have been described in the current literature. Based on the results of the diverse studies a Phase-III study using IVIG has been initiated in patients with AD. The results will show whether the application of NAbs will change the fate of the disease. This chapter summarizes our current knowledge on NAbs against Aβ.

Keywords

Alzheimer Disease Amyloid Precursor Protein Intravenous Immunoglobulin Alzheimer Disease Patient Curr Opin Immunol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 2007; 8:663–72; PMID:17684513; http://dx.doi.org/10.1038/nrn2194.PubMedCrossRefGoogle Scholar
  2. 2.
    Selkoe DJ. Alzheimer’s disease: Genes, proteins, and therapy. Physiol Rev 2001; 81:741–66; PMID:11274343.PubMedGoogle Scholar
  3. 3.
    Du Y, Dodel R, Hampel H et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001; 57:801–5; PMID: 11552007.PubMedCrossRefGoogle Scholar
  4. 4.
    Weksler ME, Relkin N, Turkenich R et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002; 37:943–8; PMID: 12086704; http://dx.doi.org/10.1016/S0531-5565(02)00029-3.PubMedCrossRefGoogle Scholar
  5. 5.
    Gaskin F, Finley J, Fang Q et al. Human antibodies reactive with beta-amyloidprotein in Alzheimer’s disease. J Exp Med 1993; 177:1181–6; PMID:8459212; http://dx.doi.org/10.1084/jem.177.4.1181.PubMedCrossRefGoogle Scholar
  6. 6.
    Gaskin F, Kingsley BS, Fu SM. Autoantibodies to neurofibrillary tangles and brain tissue in Alzheimer’s disease. Establishment of Epstein-Barr virus-transformed antibody-producing cell lines. J Exp Med 1987; 165:245–50; PMID:3025332; http://dx.doi.org/10.1084/jem.165.1.245.PubMedCrossRefGoogle Scholar
  7. 7.
    Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid7.Istrin-beta peptide. J Neurosci Res 2006; 84:434–43; PMID: 16767774; http://dx.doi.org/10.1002/jnr.20886.PubMedCrossRefGoogle Scholar
  8. 8.
    Taguchi H, Planque S, Nishiyama Y et al. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 2008; 283:4714–22; PMID:18086674; http://dx.doi.org/10.1074/jbc.M707983200.PubMedCrossRefGoogle Scholar
  9. 9.
    Kellner A, Matschke J, Bernreuther C et al. Autoantibodies against beta-amyloid are common in Alzheimer’s disease and help control plaque burden. Ann Neurol 2009; 65:24–31; PMID: 19194878; http://dx.doi.org/10.1002/ana.21475.PubMedCrossRefGoogle Scholar
  10. 10.
    Tampellini D, Magrane J, Takahashi RH et al. Internalized antibodies to the Abeta domain of APP reduce neuronal Abetaandprotectagainstsynapticalterations. J Biol Chem 2007; 282:18895–906; PMID: 17468102; http://dx.doi.org/10.1074/jbc.M700373200.PubMedCrossRefGoogle Scholar
  11. 11.
    Dodel R, Balakrishnan K, Keyvani K et al. Naturally occurring autoantibodies against β-amyloid: investigating their role in transgenic animal and in-vitro models of Alzheimer’s disease. J Neurosci 2011; 31(15):5847–54; PMID:21490226; http://dx.doi.org/10.1523/JNEUROSCI.4401-10.2011.PubMedCrossRefGoogle Scholar
  12. 12.
    Szabo P, Mujalli DM, Rotondi ML et al. Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol 2010; 227:167–74; PMID:20638733; http://dx.doi.org/10.1016/j.jneuroim.2010.06.010.PubMedCrossRefGoogle Scholar
  13. 13.
    Kasaian MT, Casali P. Autoimmunity-prone B-1 (CD5 B) cells, natural antibodies and self recognition. Autoimmunity 1993; 15:315–29; PMID:7511005; http://dx.doi.org/10.3109/08916939309115755.PubMedCrossRefGoogle Scholar
  14. 14.
    Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol 2008; 4:491–8; PMID: 18756274; http://dx.doi.org/10.1038/ncprheum0895.PubMedCrossRefGoogle Scholar
  15. 15.
    Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol 2008; 20:149–57; PMID: 18434123; http://dx.doi.org/10.1016/j.coi.2008.03.014.PubMedCrossRefGoogle Scholar
  16. 16.
    Hayakawa K, Hardy RR, Honda M et al. Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc Natl Acad Sci USA 1984; 81:2494–8; PMID:6609363; http://dx.doi.org/10.1073/pnas.81.8.2494.PubMedCrossRefGoogle Scholar
  17. 17.
    Casali P, Burastero SE, Nakamura M et al. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 1987; 236:77–81; PMID:3105056; http://dx.doi.org/10.1126/science.3105056.PubMedCrossRefGoogle Scholar
  18. 18.
    Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express thenovelphenotypeCD20+CD27+CD43+CD70. J Exp Med 2011; 208:67–80; PMID: 21220451; http://dx.doi.org/10.1084/jem.20101499.PubMedCrossRefGoogle Scholar
  19. 19.
    Dorshkind K, Montecino-Rodriguez E. Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential. Nat Rev Immunol 2007; 7:213–9; PMID: 17318232; http://dx.doi.org/10.1038/nri2019.PubMedCrossRefGoogle Scholar
  20. 20.
    Hardy RR. B-1 B cell development. J Immunol 2006; 177:2749–54; PMID: 16920907.PubMedGoogle Scholar
  21. 21.
    Kasaian MT, Ikematsu H, Casali P. Identification and analysis of a novel human surface CD521-B lymphocyte subset producing natural antibodies. J Immunol 1992; 148:2690–702; PMID:1374094.PubMedGoogle Scholar
  22. 22.
    Berland R, Wortis HH. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002; 20:253–300; PMID:11861604; http://dx.doi.org/10.1146/annurev.immunol.20.100301.064833.PubMedCrossRefGoogle Scholar
  23. 23.
    Martin F, Kearney JF. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 2001; 13:195–201; PMID:11228413; http://dx.doi.org/10.1016/S0952-7915(00)00204-1.PubMedCrossRefGoogle Scholar
  24. 24.
    Powers ET, Powers DL. Mechanisms of protein fibril formation: nucleated polymerization with competing offathway aggregation. Biophys J 2008; 94:379–91; PMID:17890392; http://dx.doi.org/10.1529/biophysj.107.117168.PubMedCrossRefGoogle Scholar
  25. 25.
    Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem 2008; 283:29639–43; PMID: 18723507; http://dx.doi.org/10.1074/jbc.R800016200.PubMedCrossRefGoogle Scholar
  26. 26.
    Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci 2001; 24:219–24; PMID: 11250006; http://dx.doi.org/10.1016/S0166-2236(00)01749-5.PubMedCrossRefGoogle Scholar
  27. 27.
    Shankar GM, Walsh DM. Alzheimer’s disease: synaptic dysfunction and Abeta. Mol Neurodegener 2009; 4:48; PMID:19930651; http://dx.doi.org/10.1186/1750-1326-4-48.PubMedCrossRefGoogle Scholar
  28. 28.
    O’Nuallain B, Acero L, Williams AD et al. Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 2008; 47:12254–6; PMID: 18956886; http://dx.doi.org/10.1021/bi801767k.PubMedCrossRefGoogle Scholar
  29. 29.
    Radaev S, Sun PD. Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J Biol Chem 2001; 276:16478–83; PMID: 11297533; http://dx.doi.org/10.1074/jbc.M100351200.PubMedCrossRefGoogle Scholar
  30. 30.
    Winkelhake JL, Kunicki TJ, Elcombe BM et al. Effects of pH treatments and deglycosylation of rabbit immunoglobulin G on the binding of C1q. J Biol Chem 1980; 255:2822–8; PMID:6965674.PubMedGoogle Scholar
  31. 31.
    Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 2009; 30:356–62; PMID: 19552968; http://dx.doi.org/10.1016/j.tips.2009.04.007.PubMedCrossRefGoogle Scholar
  32. 32.
    Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471–8; PMID:18606225; http://dx.doi.org/10.1016/j.coi.2008.06.007.PubMedCrossRefGoogle Scholar
  33. 33.
    Shields RL, Lai J, Keck R et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733–40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200.PubMedCrossRefGoogle Scholar
  34. 34.
    Rebe S, Solomon B. Deglycosylation of anti-beta amyloid antibodies inhibits microglia activation in BV-2 cellular model. Am J Alzheimers Dis Other Demen 2005; 20:303–13; PMID:16273996; http://dx.doi.org/10.1177/153331750502000511.PubMedCrossRefGoogle Scholar
  35. 35.
    Takata K, Takata-Fukae C, Becker AG et al. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Eur J Neurosci 2007; 26:2458–68; PMID:17970733; http://dx.doi.org/10.1111/j.1460-9568.2007.05852.x.PubMedCrossRefGoogle Scholar
  36. 36.
    Brettschneider S, Morgenthaler NG, Teipel SJ et al. Decreased serum amyloid beta(1–42) autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1–42) peptide. Biol Psychiatry 2005; 57:813–6; PMID: 15820240; http://dx.doi.org/10.1016/j.biopsych.2004.12.008.PubMedCrossRefGoogle Scholar
  37. 37.
    Hansson SF, Andreasson U, Wall M et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer’s disease patients. J Alzheimers Dis 2009; 16:389–97; PMID: 19221428.PubMedGoogle Scholar
  38. 38.
    Jianping L, Zhibing Y, Wei Q et al. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20:127–32; PMID:16917180; http://dx.doi.org/10.1097/00002093-200607000-00001.PubMedCrossRefGoogle Scholar
  39. 39.
    Moir RD, Tseitlin KA, Soscia S et al. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer’s disease patients. J Biol Chem 2005; 280:17458–63; PMID:15728175; http://dx.doi.org/10.1074/jbc.M414176200.PubMedCrossRefGoogle Scholar
  40. 40.
    Sohn JH, So JO, Hong HJ et al. Identification of autoantibody against beta-amyloid peptide in the serum of elderly. Front Biosci 2009; 14:3879–83; PMID: 19273318; http://dx.doi.org/10.2741/3496.PubMedCrossRefGoogle Scholar
  41. 41.
    Song MS, Mook-Jung I, Lee HJ et al. Serum anti-amyloid-beta antibodies and Alzheimer’s disease in elderly Korean patients. J Int Med Res 2007; 35:301–6; PMID:17593857.PubMedGoogle Scholar
  42. 42.
    Gruden MA, Davudova TB, Malisauskas M et al. Autoimmune responses to amyloid structures of Abeta(25–35) peptide and human lysozyme in the serum of patients with progressive Alzheimer’s disease. Dement Geriatr Cogn Disord 2004; 18:165–71; PMID: 15211072; http://dx.doi.org/10.1159/000079197.PubMedCrossRefGoogle Scholar
  43. 43.
    Mruthinti S, Buccafusco JJ, Hill WD et al. Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 2004; 25:1023–32; PMID:15212827; http://dx.doi.org/10.1016/j.neurobiolaging.2003.11.001.PubMedCrossRefGoogle Scholar
  44. 44.
    Nath A, Hall E, Tuzova M et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer’s disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med 2003; 3:29–39; PMID: 12665674; http://dx.doi.org/10.1385/NMM:3:1:29.PubMedCrossRefGoogle Scholar
  45. 45.
    Baril L, Nicolas L, Croisile B et al. Immune response to A beta-peptides in peripheral blood from patients with Alzheimer’s disease and control subjects. Neurosci Lett 2004; 355:226–30; PMID: 14732472; http://dx.doi.org/10.1016/j.neulet.2003.10.071.PubMedCrossRefGoogle Scholar
  46. 46.
    Hyman BT, Smith C, Buldyrev I et al. Autoantibodies to amyloid-beta and Alzheimer’s disease. Ann Neurol 2001; 49:808–10; PMID: 11409436; http://dx.doi.org/10.1002/ana.1061.PubMedCrossRefGoogle Scholar
  47. 47.
    Relkin NR, Mujalli D, Shennoy SA et al. IVIg contains antibodies against oligomers and fibrils of beta amyloid. Alzheimers Dement 2007; 3:S196; http://dx.doi.org/10.1016/j.jalz.2007.04.021.CrossRefGoogle Scholar
  48. 48.
    Bacher M, Depboylu C, Du Y et al. Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid antibodies in a transgenic mouse model of Alzheimer’s disease. Neurosci Lett 2009; 449:240–5; PMID: 18786612; http://dx.doi.org/10.1016/j.neulet.2008.08.083.PubMedCrossRefGoogle Scholar
  49. 49.
    Dodel R, Hampel H, Depboylu C et al. Human antibodies against amyloid beta peptide: apotential treatment for Alzheimer’s disease. Ann Neurol 2002; 52:253–6; PMID:12210803; http://dx.doi.org/10.1002/ana.10253.PubMedCrossRefGoogle Scholar
  50. 50.
    O’Nuallain B, Hrncic R, Wall JS et al. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol 2006; 176:7071–8; PMID: 16709869.PubMedGoogle Scholar
  51. 51.
    Dodel R, Neff F, Noelker C et al. Intravenous immunoglobulins as a treatment for Alzheimer’s disease: rationale and current evidence. Drugs 2010; 70:513–28; PMID:20329802; http://dx.doi.org/10.2165/11533070-000000000-00000.PubMedCrossRefGoogle Scholar
  52. 52.
    Kountouris D. Therapeutic effects of piracetam combined with intravenous immunoglobulin premature of Alzheimer type. J Neural Transm 2000; 107:18.Google Scholar
  53. 53.
    Dodel RC, Du Y, Depboylu C et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for thetreatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004; 75:1472–4; PMID:15377700; http://dx.doi.org/10.1136/jnnp.2003.033399.PubMedCrossRefGoogle Scholar
  54. 54.
    Relkin NR, Szabo P, Adamiak B et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009; 30:1728–36; PMID: 18294736; http://dx.doi.org/10.1016/j.neurobiolaging.2007.12.021.PubMedCrossRefGoogle Scholar
  55. 55.
    www.clinicaltrials.gov. Study of Octagam 10% on theTreatment of Mildto Moderate Alzheimer’s Patients. NCT00812565 2009.
  56. 56.
    www.clinicaltrials.gov. A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease. NCT00818662 2009.
  57. 57.
    Fillit H, Hess G, Hill J et al. cIV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009; 73:180–5; PMID: 19620605; http://dx.doi.org/10.1212/WNL.0b013e3181ae7aaf.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2012

Authors and Affiliations

  1. 1.Department of NeurologyPhilipps-University MarburgGermany

Personalised recommendations